SCO­TUS just turned its back on Al­ler­gan’s le­gal ma­neu­ver to take a blow at in­ter partes re­view. What did you ...

7 years ago
Bioregnum
Opinion

Ad­verum Bio of­fers a late no­ti­fi­ca­tion about FDA hold on lead gene ther­a­py for wet AMD

7 years ago
Cell/Gene Tx

In­sys pro­motes CFO to the helm as Saeed Mo­ta­hari hits the ex­it; Gele­sis gets OK to mar­ket weight loss treat­ment

7 years ago
News Briefing

Fi­bro­cell Sci­ence sees light at the end of the tun­nel with Cas­tle Creek deal to de­vel­op 'but­ter­fly' dis­ease gene ...

7 years ago
Cell/Gene Tx

Four biotech Nas­daq wannabes out­line IPO plans — and don't miss Chi-Med's HKEX pitch

7 years ago
Financing

In­flu­en­tial proxy firms kick back at ac­tivists’ de­mands for Brent Saun­ders to give up his chair­man’s ti­tle at ...

7 years ago
People

Road war­rior: Hal Bar­ron's glob­al R&D cru­sade at GSK comes with a hefty $800,000-plus trav­el bud­get

7 years ago
People

This ven­ture play­er is plot­ting $200M in new biotech in­vest­ing — and they’re dou­bling down on a start­up-rich ...

7 years ago
Financing

Ahead of US gene ther­a­py ex­plo­sion, big con­tract drug man­u­fac­tur­er Catal­ent makes $1.2 bil­lion bet on Paragon ...

7 years ago
Deals
Outsourcing

Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

7 years ago
R&D

Al­ny­lam spot­lights just how good the ef­fi­ca­cy da­ta are for givosir­an — tamp­ing down on safe­ty con­cerns

7 years ago
Startups
R&D

Clo­vis shut­ters PhII Rubra­ca study af­ter da­ta mon­i­tors turn thumbs down on ef­fi­ca­cy

7 years ago
R&D

J&J nabs ac­cel­er­at­ed FDA OK for one of their top late-stage drugs

7 years ago
R&D

Mer­ck­'s Keytru­da wins US ap­proval for wider lung can­cer pop­u­la­tion; CymaBay breaks out pos­i­tive da­ta from on­go­ing PBC ...

7 years ago
News Briefing

Bris­tol-My­ers share­hold­ers back the big Cel­gene buy­out. What hap­pens now?

7 years ago
Deals

This Chi­nese phar­ma filed for an IPO last Sep­tem­ber. Sev­en months and a $283M in­vest­ment lat­er, they are back at the ...

7 years ago
Financing
China

Peer Re­view: Leav­ing Cere­cor af­ter a year, Pe­ter Green­leaf starts a new CEO chap­ter at Au­rinia — out to slay ...

7 years ago
Peer Review

Sonde wants to lis­ten for dis­ease — M Ven­tures heard the Boston biotech, and led a $16M round to su­per­charge ...

7 years ago
Financing
Startups

Still ear­ly stage, but this Flag­ship up­start re­cruit­ed a Big Phar­ma ex­ec with a $4.3M com­pen­sa­tion pack­age and an IPO ...

7 years ago
Financing

Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

7 years ago
Bioregnum
R&D

FDA tells Sprout Phar­ma, like it or not the black box on Ad­dyi stays, but we will di­lute the warn­ing

7 years ago
Pharma

A block­buster cock­tail? Gilead slides No­vo Nordisk's semaglu­tide in­to new NASH triple ther­a­py

7 years ago
R&D
Pharma

Cam­brex com­pletes $24M API man­u­fac­tur­ing fa­cil­i­ty; Twist and LakePhar­ma part­ner on an­ti­body con­tract work

7 years ago
News Briefing

Two Syn­cona-backed play­ers join forces to take on reti­nal gene ther­a­pies

7 years ago
Deals
Cell/Gene Tx
First page Previous page 958959960961962963964 Next page Last page
A service from the Financial Times